The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Brecht Chys
No Relationships to Disclose
 
Christopher Jean
No Relationships to Disclose
 
Fred Saad
Honoraria - Abbvie; Advanced Accelerator Applications; Astellas Pharma; AstraZeneca; Bayer; BMS; GlaxoSmithKline; Janssen Oncology; Knight Therapeutics; Merck; Myovant Sciences; Novartis; Pfizer; Sanofi; Sumitomo Dainippon Pharma Oncology; Tolmar
Consulting or Advisory Role - Abbvie; Advanced Accelerator Applications; Astellas Pharma; AstraZeneca/MedImmune; Bayer; GlaxoSmithKline; Janssen Oncology; Knight Therapeutics; Myovant Sciences; Novartis; Pfizer; Sanofi; Sumitomo Dainippon Pharma Oncology; Tolmar
Research Funding - Abbvie (Inst); Advanced Accelerator Applications (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Point Therapeutics (Inst); Sanofi (Inst)
 
Étienne Rousseau
Employment - Alpha-9 Theranostics (I)
Stock and Other Ownership Interests - Alpha-9 Theranostics (I)
Patents, Royalties, Other Intellectual Property - Bénard F, Lin KS, Rousseau E, Zhang Z, Kwon D, Lau J, Uribe-Munoz C, Lozada J, Perrin D. Novel radiolabelled cxcr4-targeting compounds for diagnosis and therapy, US Patent US20220218852A1 (Published 2022-07-14), Priority to 62835733
 
Patrick Richard
Honoraria - Abbvie; Astellas Pharma; Bayer; Knight Pharmaceuticals; Novartis; Tolmar
Consulting or Advisory Role - Bayer; ClarityDx; Novartis
Travel, Accommodations, Expenses - Bayer
 
Atefeh Zamanian
No Relationships to Disclose
 
Frederic Pouliot
Stock and Other Ownership Interests - Allogene Therapeutics
Honoraria - Astellas Pharma; Bayer; Janssen; Novartis; Tersera; Tolmar
Consulting or Advisory Role - Astellas Pharma; Bayer; Janssen; Merck; Tersera; Tolmar
Research Funding - Astellas Pharma (Inst); Janssen (Inst); Merck (Inst); Novartis; Tersera (Inst)
Patents, Royalties, Other Intellectual Property - Transcriptional system and uses therof for single cell detection
 
Brigitte Guérin
Research Funding - AL-S Pharma AG (Inst)
Patents, Royalties, Other Intellectual Property - PCT/CA2019/051777 License to Trasis
 
Jean-Mathieu Beauregard
Honoraria - Novartis
Consulting or Advisory Role - Novartis Canada Pharmaceuticals Inc
Research Funding - Novartis (Inst); Point Biopharma (Inst)
 
Louis Archambault
No Relationships to Disclose